Outcomes in orthopedic device infections due to Streptococcus agalactiae: a retrospective cohort study

BMC Infect Dis. 2024 Apr 22;24(1):424. doi: 10.1186/s12879-024-09175-6.

Abstract

Background: Group B streptococci (Streptococcus agalactiae) (GBS) is a rare cause of prosthetic joint infection (PJI) occurring in patients with comorbidities and seems to be associated with a poor outcome. Depiction of GBS PJI is scarce in the literature.

Methods: A retrospective survey in 2 referral centers for bone joint infections was done Patients with a history of PJI associated with GBS between 2014 and 2019 were included. A descriptive analysis of treatment failure was done. Risk factors of treatment failure were assessed.

Results: We included 61 patients. Among them, 41 had monomicrobial (67%) infections. The median duration of follow-up was 2 years (interquartile range 2.35) Hypertension, obesity, and diabetes mellitus were the most reported comorbidities (49%, 50%, and 36% respectively). Death was observed in 6 individuals (10%) during the initial management. The rate of success was 63% (26/41). Removal of the material was not associated with remission (p = 0.5). We did not find a specific antibiotic regimen associated with a better outcome.

Conclusion: The results show that S. agalactiae PJIs are associated with high rates of comorbidities and a high treatment failure rate with no optimal treatment so far.

Keywords: Streptococcus agalactiae; Group B streptococci; Joint infection; Prosthetic.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents* / therapeutic use
  • Comorbidity
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prosthesis-Related Infections* / drug therapy
  • Prosthesis-Related Infections* / microbiology
  • Retrospective Studies
  • Risk Factors
  • Streptococcal Infections* / drug therapy
  • Streptococcal Infections* / epidemiology
  • Streptococcal Infections* / microbiology
  • Streptococcus agalactiae*
  • Treatment Failure
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents